Tag: pharmaceuticals
-
Hemophilia Therapy Candidate Given Breakthrough Status
4 September 2015. A synthetic antibody designed to prevent bleeding episodes among people with the most common type of hemophilia received a breakthrough therapy designation from the U.S. Food and Drug Administration. The pharmaceutical company Roche says FDA assigned the designation its biologic therapy code-named ACE910, now being tested in clinical trials. Hemophilia is an inherited…
-
Cancer Labs Crowdsource Drug Discovery
3 September 2015. Ontario Institute for Cancer Research and Structural Genomics Consortium are making an early-stage drug prototype freely available to the biomedical research community to further define its therapeutic capabilities. Financial and intellectual property aspects of the offer were not immediately disclosed. The two research labs — both in Toronto, Ontario, Canada — jointly…
-
Technique Devised to Deliver Small Drug Amounts to Lungs
3 September 2015. Engineers and medical researchers at Columbia University developed a technique that delivers small amounts of medications in liquid form to specific areas of lungs. The team led by biomedical engineering professor Gordana Vunjak-Novakovic published its proof-of-concept findings earlier this week in Proceedings of the National Academy of Sciences (paid subscription required). The…
-
Preventive Drugs Found to Stop New HIV Infections
2 September 2015. A large-scale study of preexposure prophylaxis or PrEP, the use of antiviral drugs to prevent HIV infection, found the practice prevented new HIV infections among Kaiser Permanente clients in San Francisco over a 32-month period. Results of the study led by Kaiser Permanente epidemiologist Jonathan Volk, appear in yesterday’s issue of the…
-
Genome Editing Biotech Gains $70M in Venture Funds
1 September 2015. Intellia Therapeutics, a developer of therapies that edit human genomes to fix inherited disorders, raised $70 million in its second round of venture financing. OrbiMed HealthCare Fund Management led the funding round for the Cambridge, Massachusetts enterprise, with new and current investors taking part. Intellia Therapeutics, founded in November 2014, is a…
-
Grant Funds Research on Nanotech Cancer Treatments
1 September 2015. National Cancer Institute is renewing its support for a Northwestern University research center advancing nanotechnology to design new cancer treatments. The Northwestern University Center for Cancer Nanotechnology Excellence is the recipient of a new five-year, $11.7 million grant from National Cancer Institute, part of National Institutes of Health. The Center for Cancer…
-
FDA Proposes Guidance, Rule on Biosimilar Naming
28 August 2015. The U.S. Food and Drug Administration proposed new guidance yesterday to provide a common, nonproprietary naming system for generic forms of biologic treatments, known as biosimilars. The agency also proposed a rule applying the system to six biologics and biosimilars already approved, announced with the guidance in a blog post on the…
-
Allied-Bristol Licensing Immunotherapy Technology
27 August 2015. Allied-Bristol Life Sciences, a joint venture of science commercialization company Allied Minds and Bristol-Myers Squibb, is licensing a new type of synthetic chemistry technology from Yale University that can stimulate the immune system to treat cancer. Financial details of the licensing agreement were not disclosed. The agreement covers a technology known as…
-
Trial Shows Response to Antibody Treating Multiple Myeloma
27 August 2015. An early-stage clinical trial shows some patients receiving an engineered antibody to attack multiple myeloma cancer cells experienced at least a partial remission of their disease. Results of the study, led by oncologist Paul Richardson of Dana-Farber Cancer Institute and Harvard Medical School, appeared yesterday in New England Journal of Medicine. Multiple…
-
Pharma, Research Group Partner on Meningitis Therapy
26 August 2016. A collaboration between a company developing anti-fungal drugs and research group specializing in fungal infections aims to advance a new type of therapy for cryptococcal meningitis, a life-threatening infection affecting the brain and spinal cord. Financial details of the partnership between Viamet Pharmaceuticals in Research Triangle Park, North Carolina and Mycoses Study Group Education and Research Consortium in Birmingham,…